Plunkett Research Online: Resverlogix Corp

RESVERLOGIX CORP (RVX:TSE) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Resverlogix Corp clinical stage biotechnology company. Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative dise.....



Resverlogix Corp
Ticker: RVX
Exchange: TSE
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 403 254-9252
Fax: 1 403 256-8495
Address: 4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1 Canada

Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines, Skin Replacement Products and Biologicals Manufacturing
ContactsDescription
Donald McCaffreyCEO/Co-Founder/Director/President/Secretary/Chairman of the Board
A. CannCFO
See More
Resverlogix Corp clinical stage biotechnology company. Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative dise.....See More See More

Auditor: KPMG LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201820172016201520142013
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: